DelveInsight’s “Alpha-Mannosidosis Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding of the market dynamics, competitive landscape, key growth drivers, emerging therapies, and future opportunities shaping the global alpha-mannosidosis therapeutics landscape.
Interested to know which alpha-mannosidosis therapies will capture the highest market share?
Download the report to understand the latest alpha-mannosidosis market trends and forecasts – https://www.delveinsight.com/report-store/alpha-mannosidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr
Key Takeaways from the Alpha-Mannosidosis Market Report
The global alpha-mannosidosis market in the 7MM is expected to change significantly during the forecast period 2026–2036. Rising identification of alpha-mannosidosis cases driven by improved disease recognition, enhanced clinical awareness, and expanding newborn screening programs is increasing demand for effective therapeutic solutions. Growing adoption of enzyme replacement therapy, particularly velmanase alfa-tycv (LAMZEDE), following regulatory approvals in the US and EU, is accelerating market uptake. Technological advancements in genetic testing, newborn screening, and molecular diagnostics are enabling earlier and more frequent identification of affected individuals across the 7MM. Gene therapies, CNS-targeted treatments, and potentially curative approaches represent major emerging opportunities in the alpha-mannosidosis pipeline. The United States held a significant share of the overall 7MM alpha-mannosidosis market in 2025, primarily attributed to higher prevalence of the condition and elevated treatment costs. Significant unmet needs persist, as current management approaches do not provide a cure and have limited impact on neurological disease progression, creating opportunities for next-generation therapies. Leading alpha-mannosidosis companies include Chiesi Farmaceutici S.p.A, and others.
Gain a competitive edge in the Alpha-Mannosidosis Market by exploring our in-depth analysis @ Alpha-Mannosidosis Market Report – https://www.delveinsight.com/report-store/alpha-mannosidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr
Alpha-Mannosidosis Market Overview
The global alpha-mannosidosis market is progressing through a period of gradual but meaningful growth, driven by a single approved pharmacological intervention and sustained research interest in the lysosomal storage disorder space. Alpha-mannosidosis is a rare inherited lysosomal storage disorder caused by mutations in the MAN2B1 gene, leading to a deficiency of the enzyme alpha-D-mannosidase. This enzyme deficiency results in the accumulation of mannose-rich oligosaccharides in cells, causing progressive damage to multiple organs and tissues.
Growing recognition of the disease, combined with expanding newborn screening programs enabling earlier and presymptomatic diagnosis, continues to support market growth. The integration of genetic testing, molecular diagnostics, and multidisciplinary management has further broadened the clinical approach to alpha-mannosidosis across diagnosis, treatment monitoring, and long-term care.
Factors Driving the Growth of the Alpha-Mannosidosis MarketRising Disease Identification and Clinical Awareness
The increasing number of reported alpha-mannosidosis cases is primarily attributable to improved disease recognition. Enhanced understanding of rare lysosomal storage disorders, identification of pathogenic variants in the MAN2B1 gene leading to alpha-mannosidase enzyme deficiency, and growing clinical awareness among physicians have collectively contributed to improved diagnostic rates across the 7MM.
Expanding Newborn Screening Programs
The expansion of newborn screening and genetic testing programs across the 7MM is facilitating earlier and more frequent identification of affected individuals. Earlier presymptomatic diagnosis is expected to increase the pool of treated patients and support greater uptake of available therapies during the forecast period.
Approval and Uptake of Velmanase Alfa-tycv (LAMZEDE)
Velmanase alfa-tycv (LAMZEDE) by Chiesi Farmaceutici S.p.A, the first and only approved enzyme replacement therapy for alpha-mannosidosis, serves as the cornerstone of the current treatment landscape. Its increasing uptake following regulatory approvals in the US (2023) and EU (2018) is a primary driver of market revenue growth.
Significant Unmet Needs Driving R&D Activity
Significant unmet needs persist within the alpha-mannosidosis treatment landscape. Current management approaches do not provide a cure, have limited impact on neurological disease progression, and require lifelong administration. These limitations create opportunities for next-generation therapeutic strategies, including gene therapies, CNS-targeted treatments, and potentially curative approaches capable of addressing both systemic and neurological manifestations.
New Alpha-Mannosidosis Companies and Research Programs
The lysosomal storage disorder space continues to attract research investment, with Chiesi supporting ongoing research efforts in alpha-mannosidosis. While the development pipeline remains notably sparse, a small number of preclinical programs are under evaluation, and broader innovation is anticipated during the forecast period.
Alpha-Mannosidosis Market Segment Analysis
The alpha-mannosidosis therapeutics market is currently dominated by velmanase alfa-tycv (LAMZEDE), which represents the only approved pharmacological therapy for the condition. The market is segmented by therapies and by countries across the 7MM. In 2025, the US held a significant share of the overall 7MM alpha-mannosidosis market, primarily attributed to the country’s higher prevalence of the condition and the elevated cost of available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.
Alpha-Mannosidosis Market Regional AnalysisNorth America is Expected to Dominate the Overall Alpha-Mannosidosis Market
North America, led by the United States, is anticipated to maintain the largest market share owing to higher disease prevalence, elevated treatment costs, strong reimbursement frameworks, and regulatory support for orphan therapies.
The prevalence of alpha-mannosidosis is estimated to be 1 in every 500,000 people in the general population in the US. The country’s dominance is projected to persist throughout the forecast period, especially with the potential early introduction of new therapeutic products.
Europe continues to contribute meaningfully to the global alpha-mannosidosis market. In Germany, structured multidisciplinary management and growing awareness of enzyme replacement therapy are supporting patient identification and treatment uptake. In Italy, the estimated prevalence of alpha-mannosidosis ranges from approximately 1 in 250,000 to 1 in 1 million live births, underscoring its classification as an ultra-rare lysosomal storage disorder. France, Spain, and the United Kingdom also represent important markets as precision diagnosis and genetic testing expand access to diagnosis and therapy. Japan similarly forms part of the 7MM geographic scope of the report.
Alpha-Mannosidosis Key Companies
Alpha-Mannosidosis Companies include:
Chiesi Farmaceutici S.p.A And Others.
Download the report to understand which factors are driving Alpha-Mannosidosis Market Trends
Latest Highlights from the Alpha-Mannosidosis Market
In February 2023, Chiesi Farmaceutici S.p.A reported that the US Food and Drug Administration (FDA) approved velmanase alfa-tycv (LAMZEDE) for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients. In April 2018, the European Commission granted marketing authorization for velmanase alfa-tycv (LAMZEDE) for the treatment of non-neurological manifestations in individuals with mild to moderate alpha-mannosidosis. Expansion of newborn screening programs across the 7MM is facilitating earlier and more frequent identification of affected individuals, increasing the diagnosed patient pool. Hematopoietic stem cell transplantation (HSCT) continues to be explored in selected patients with severe disease as a complementary option to enzyme replacement therapy. Chiesi continues to support research efforts in alpha-mannosidosis, while broader innovation in the space is expected to grow during the forecast period with gene therapies and CNS-targeted approaches under evaluation. Multidisciplinary management models spanning metabolic physicians, geneticists, neurologists, audiologists, physiotherapists, and immunologists are increasingly recognized as the standard of care.
Discover key developments and opportunities in the Alpha-Mannosidosis Market @ Alpha-Mannosidosis Market Size
Alpha-Mannosidosis Market Outlook
The alpha-mannosidosis market is experiencing gradual but steady growth as healthcare systems increasingly embrace rare disease diagnosis and management. Advances in genetic testing, newborn screening, enzyme replacement therapy, and multidisciplinary care are significantly improving the clinical approach to this ultra-rare lysosomal storage disorder.
The market is also benefiting from expanding recognition of unmet needs, particularly the lack of effective therapies targeting neurological manifestations, which is driving sustained R&D activity in gene therapies and CNS-targeted treatment approaches. Growing investments, strategic partnerships, and regulatory support for orphan conditions are expected to further accelerate innovation and commercialization.
As precision medicine in rare diseases continues to gain momentum, alpha-mannosidosis therapies are positioned to evolve significantly during the forecast period 2026–2036, enabling earlier intervention, improved patient outcomes, and more personalized treatment strategies across the US, EU4, the UK, and Japan.
Scope of the Alpha-Mannosidosis Market Report
Study Period: 2022–2036
Forecast Period: 2026–2036
Major Alpha-Mannosidosis Companies: Chiesi Farmaceutici S.p.A, and others.
Market Segments Covered: Total Market Size, Market Size by Therapies, and Geography.
Geographies Covered: North America (The United States), Europe (Germany, France, Italy, Spain, and the United Kingdom), and Asia-Pacific (Japan).
Competitive Intelligence Analysis: Market trends, competitive landscape, SWOT analysis, market entry strategies, conjoint analysis, KOL views, unmet needs, and emerging therapeutic approaches.
Key Focus Areas: Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplantation (HSCT), Gene Therapy, CNS-Targeted Treatments, Newborn Screening, and Molecular Diagnostics in Alpha-Mannosidosis.
Table of Contents
Key Insights
Report Introduction
Market Overview at a Glance
Epidemiology and Market Methodology
Executive Summary
Key Events
Disease Background and Overview
Epidemiology and Patient Population
Patient Journey
Marketed Therapies
Alpha-mannosidosis: Seven Major Market Analysis
Key Opinion Leaders’ Views
Unmet Needs
SWOT Analysis
Alpha-mannosidosis Market Access and Reimbursement
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight
How DelveInsight’s Alpha-Mannosidosis Market Report Helps CXOs and Business Leaders
Evaluate the current and future market opportunity across key regions, including the United States, EU4, the United Kingdom, and Japan, through detailed market forecasts, epidemiology assessments, and growth trend analysis. Benchmark the only approved alpha-mannosidosis therapy and assess emerging pipeline candidates through comprehensive competitive intelligence, company profiling, product portfolio evaluation, and innovation tracking. Identify potential licensing, acquisition, co-development, and strategic partnership opportunities by monitoring emerging market participants, novel therapeutic technologies, and recent industry collaborations, mergers, and investments. Assess the impact of upcoming regulatory approvals, technological advancements, reimbursement developments, and product launches on market share, pricing strategies, adoption rates, and commercial success. Support strategic decision-making with insights into key opinion leader (KOL) perspectives, unmet treatment needs, clinical adoption trends, patient stratification approaches, and evolving market dynamics within the Alpha-Mannosidosis landscape.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Abhishek kumarEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
